Abstract
Factor Xa (fXa) is the vitamin K-dependent serine protease of the prothrombinase complex (fXa, factor Va, negatively charged membrane, and calcium) which is responsible for the conversion of prothrombin to thrombin in the final stage of the coagulation cascade. The proteolytic activity of fXa in plasma is primarily regulated by three physiological inhibitors, antithrombin (AT), protein Z-dependent protease inhibitor (ZPI) and tissue factor pathway inhibitor (TFPI). The first two inhibitors belong to the serpin family of plasma inhibitors, both of which require cofactors for their effective interaction with fXa. Thus, the AT interaction with the heparin-like glycosaminoglycans on the surface of the endothelium, and the ZPI complex formation with protein Z on membrane phospholipids is required for the physiological regulation of fXa by both serpins. On the other hand, TFPI is a slow and tight-binding, Kunitz type inhibitor that is capable of rapidly inhibiting fXa independent of a cofactor. This article will review the structural features that enable fXa to specifically interact with these three inhibitors under different conditions.
Keywords: Factor Xa, antithrombin, PZ-dependent protease inhibitor, Tissue factor pathway inhibitor, Serpin, Kunitz inhibitor
Mini-Reviews in Medicinal Chemistry
Title: Determinants of Specificity of Factor Xa Interaction with its Physiological Inhibitors
Volume: 6 Issue: 8
Author(s): Alireza R. Rezaie
Affiliation:
Keywords: Factor Xa, antithrombin, PZ-dependent protease inhibitor, Tissue factor pathway inhibitor, Serpin, Kunitz inhibitor
Abstract: Factor Xa (fXa) is the vitamin K-dependent serine protease of the prothrombinase complex (fXa, factor Va, negatively charged membrane, and calcium) which is responsible for the conversion of prothrombin to thrombin in the final stage of the coagulation cascade. The proteolytic activity of fXa in plasma is primarily regulated by three physiological inhibitors, antithrombin (AT), protein Z-dependent protease inhibitor (ZPI) and tissue factor pathway inhibitor (TFPI). The first two inhibitors belong to the serpin family of plasma inhibitors, both of which require cofactors for their effective interaction with fXa. Thus, the AT interaction with the heparin-like glycosaminoglycans on the surface of the endothelium, and the ZPI complex formation with protein Z on membrane phospholipids is required for the physiological regulation of fXa by both serpins. On the other hand, TFPI is a slow and tight-binding, Kunitz type inhibitor that is capable of rapidly inhibiting fXa independent of a cofactor. This article will review the structural features that enable fXa to specifically interact with these three inhibitors under different conditions.
Export Options
About this article
Cite this article as:
Rezaie R. Alireza, Determinants of Specificity of Factor Xa Interaction with its Physiological Inhibitors, Mini-Reviews in Medicinal Chemistry 2006; 6 (8) . https://dx.doi.org/10.2174/138955706777935017
DOI https://dx.doi.org/10.2174/138955706777935017 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heat Transfer Analysis on Transport of Copper Nanofluids Due to Metachronal Waves of Cilia
Current Nanoscience Management of Acute Coronary Syndromes in Patients with Renal Insufficiency
Current Cardiology Reviews Potential Therapeutic Targets in Cirrhotic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets 6-(Arylaminomethyl) Isoquinolines as Enzyme Inhibitors and Their Preparation: A Patent Highlight of Factor XIIa Inhibitors
Cardiovascular & Hematological Agents in Medicinal Chemistry New Developments on Thromboxane and Prostacyclin Modulators Part I: Thromboxane Modulators
Current Medicinal Chemistry Depression and Cardiovascular Disease: Role of Nitric Oxide
Cardiovascular & Hematological Agents in Medicinal Chemistry Effect of Administration of Nandrolone Decanoate upon Aldosterone Concentration and Serum Na+/K+ Levels in Albino Mice
Cardiovascular & Hematological Agents in Medicinal Chemistry Biomarkers in Post-stroke Depression
Current Neurovascular Research New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry The Role of Tirofiban in the Management of Coronary Artery Disease
Cardiovascular & Hematological Disorders-Drug Targets Sildenafil in Combination Therapy against Cancer: A Literature Review
Current Medicinal Chemistry Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment
Current Alzheimer Research Freud Meets Bill W: A Model for the Dynamics of Alcoholics Anonymous
Adolescent Psychiatry Novel Hybrid Anticonvulsants Derived from Pyrrolidine-2,5-dione Scaffold with Broad Spectrum of Activity in the Preclinical Studies
Current Topics in Medicinal Chemistry Are Raw Scores on Memory Tests Better than Age- and Education- Adjusted Scores for Predicting Progression from Amnesic Mild Cognitive Impairment to Alzheimer Disease ?
Current Alzheimer Research Review of Synthesis, Biological Assay, and QSAR Studies of HMGR Inhibitors
Current Topics in Medicinal Chemistry Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Nucleic Acid Drugs for Preventing Restenosis after Coronary Revascularization
Current Topics in Medicinal Chemistry Assessment of Short- and Long-Term Outcomes of Patients Hospitalized With Intracerebral Hemorrhage
Current Neurovascular Research Superior Neuroprotective Effects of Cerebrolysin in Nanoparticle-Induced Exacerbation of Hyperthermia-Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets